Medscape2d
Pembrolizumab Approved With Chemotherapy for Malignant Pleural Mesothelioma
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...
HealthDay on MSN2d
Pembrolizumab + Chemo Beneficial for Early-Stage Triple-Negative Breast Cancer
For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Medpage Today on MSN4d
Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer
Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...
Business Insider5d
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
The ESMO Proferred Paper Oral Presentation slides are available on the Posters & Publications ... in combination with MSD’s ...
Pharmabiz5d
Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY-101 in solid tumors
Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY-101 in solid tumors: Bergen, Norway Monday, September 16, 2024, 18:00 Hrs [IST ...
Morningstar8d
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
The poster can be found on the “Posters ... IO Biotech is sponsoring the Phase 2 trial and Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.